Apimeds Pharmaceuticals US, Inc. operates as a clinical stage biopharmaceutical company in the United States. It researches, develops, manufactures, commercializes, and sells Apitox, an active pharmaceutical ingredient for the treatment of inflammation and pain management symptoms associated with osteoarthritis and multiple sclerosis. The company was incorporated in 2020 and is based in Hopewell, New Jersey. Apimeds Pharmaceuticals US, Inc. is a subsidiary of Api Meds, Inc.

Company Data

Name Apimeds Pharmaceuticals US, Inc. Common Stock

Company Apimeds Pharmaceuticals US, Inc

Symbol APUS

Website https://www.apimedsus.com

Primary Exchange

NYSE

ISIN US03771D1028

Asset Class Share

Sector Healthcare

Industry Drug Manufacturers - Specialty & Generic

CEO Erik C. Emerson

Market Capitalization 18 Mio

Country United States of America

Currency USD

Employees 0,0 T

Address 2 East Broad Street, 08525 Hopewell

IPO Date 2025-05-09

Ticker Symbols

Name	Symbol
NYSE	APUS

More Shares

Investors who hold Apimeds Pharmaceuticals US, Inc. Common Stock also have the following shares in their portfolio:

ASTM 21/30 MTN Bond

Phihong Technology Co., Ltd. Share

The financial platform MoneyPeak tracks and analyzes investments and portfolios. From securities portfolios to crypto purchases.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.

Imprint Data Protection Blog Community Feedback Changelog